R
Rocket Pharmaceuticals
Rocket Pharmaceuticals Ltd operates in the healthcare industry focusing on biotechnology business
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, accessible at rocketpharma.com, is a pioneering biotech startup focused on developing gene therapies for patients suffering from severe and rare inherited diseases. The company operates in the highly specialized field of gene therapy, which involves altering genes within a patient's cells to treat or prevent disease. Rocket Pharmaceuticals primarily serves patients and families affected by rare genetic disorders, aiming to provide life-changing treatments where few or no options currently exist.
The company leverages an advanced platform known as AAV (Adeno-Associated Virus) to deliver corrected genes directly into patients' bodies. This platform is particularly effective for disorders impacting the heart, liver, eye, or central nervous system. By engineering specific AAV constructs, Rocket Pharmaceuticals ensures that the corrected gene is expressed in the targeted diseased cells, producing a therapeutic protein that can modify the disease.
Rocket Pharmaceuticals operates on a business model that combines cutting-edge scientific research with a patient-centric approach. The company generates revenue through various channels, including partnerships with larger pharmaceutical companies, grants, and potentially future sales of approved therapies. Their mission is to develop both "first-in-class" and "best-in-class" gene therapies, meaning they aim to create the first available treatment for a condition or the best treatment among available options.
The company's core values—Trust, Generosity, Curiosity, and Elevation—are integral to its operations. These values guide their commitment to putting patients and their families first, fostering a supportive community, and continually advancing their scientific expertise to maximize treatment outcomes.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2015
- Headquarters
- Cranbury Township, United States
- Listing
- IPO 2018
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
California Institute for Regenerative Medicine
Series A1 investor entered at this stage
Cantor Fitzgerald
Series B and later1 investor entered at this stage
RTW Investments
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
23 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rocket Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rocket Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

